Navigation Links
Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration
Date:8/15/2012

NEW YORK, Aug. 15, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for the Company's proprietary chemosaturation system for use with melphalan hydrochloride in the treatment of patients with unresectable metastatic melanoma in the liver. The Company included its Generation 2 filter in its NDA submission as a technical change to the Chemistry, Manufacturing, and Control (CMC) module.

"Our team has achieved a significant milestone with the filing of our NDA," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "We believe that our chemosaturation system provides the opportunity to satisfy a high unmet medical need to treat patients with unresectable metastatic melanoma in the liver. We also believe including our Generation 2 filter in the CMC module represents the fastest regulatory review path for the Generation 2 system, and that it is in the best interest of U.S. patients that we accelerate the potential availability of Generation 2."

"We have requested priority review of our NDA by the FDA. Assuming the NDA is accepted and that priority review is granted, our expected Prescription Drug User Fee Act (PDUFA) date would be in February of next year.  Based upon the strength of our Phase 1, 2 and 3 data, along with the limited treatment options available for patients with unresectable melanoma metastases in the liver, we believe that our application meets the FDA's criteria for priority review."

In Delcath's Phase 3 clinical trial (April 2010 data cutoff), comparing treatment with the Company's proprietary chemosaturation system to best alternative care (BAC) revealed that patients treated with chemosaturation therapy experienced a statistically significant extension in median hepatic progression free survival (hPFS) o
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
6. Delcath Announced Changes To Board Of Directors
7. Delcath To Present At JMP Securities Healthcare Conference On July 12
8. Delcath To Conduct Second Quarter 2012 Results Conference Call
9. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
10. Delcath To Present At Upcoming Investor Conferences
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Physician-Patient Alliance for Health & Safety announced ... the Physician-Patient Alliance Board of Advisors. ... who has practiced in the post-acute care arena since ... on critical patient safety issues. He has represented the ... various conferences addressing the need for patient monitoring and ...
(Date:4/28/2015)... , April 28, 2015  Olympus, a precision technology ... and surgical procedures, among other core businesses, announced today ... Brooklyn Park, MN. The new ... designed to position the company for continued long-term growth ... dedication ceremony took place on April 27 and was ...
(Date:4/28/2015)... , April 28, 2015 A new ... Personal Prescription Importation (CPPI) , has launched today ... prescription medications from Canada ... of Americans – especially the elderly and others ... extremely high price of prescription medications in the ...
Breaking Medicine Technology:Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 2Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 3
... The U.S. Food and Drug Administration today is ... that include a new standardized format to improve readability ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Merck,s ... labels for 16 solid oral drug products regulated by ...
... 2011 The U.S. Food and Drug Administration today ... to simultaneously perform a positron emission tomography scan, commonly ... (MRI) scan. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... how the organs and tissues inside the body are ...
Cached Medicine Technology:FDA Approves Redesigned Labels for Some Merck Drugs 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 3
(Date:4/28/2015)... Petersburg, FL (PRWEB) April 28, 2015 ... Health System were named to Becker's Hospital Review’s ... Safety . Peter Pronovost, M.D., Ph.D. , director ... Quality and senior vice president for patient safety ... Mueller, M.D., M.H.C.M. , vice president of medical affairs ...
(Date:4/28/2015)... 2015 The popular all-natural supplement brand, ... their newly launched L-Style Revolution Program™, and collectively the ... in just two short months. The customized weight ... plan for men and women of all health and ... and weight maintenance goals faster than traditional methods. , ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 An ... Blair A. Jobe, MD, FACS , has launched the ... tissue with extracellular matrix (ECM) can help patients who ... of esophageal cancer. , ECM is a complex mixture ... attachment and migration and signals that guide cell behavior. ...
(Date:4/28/2015)... As the Muscular Dystrophy Association continues ... the organization has hired Scientific Program Officer Lianna ... Fidelity Biosciences Research Initiative where, as Associate Director, ... diseases such as Alzheimer’s Disease, and organized and ... Fidelity, she was a junior faculty member at ...
(Date:4/28/2015)... 28, 2015 Researchers from four US ... of a steroid prior to pemetrexed (Alimta) chemotherapy may ... Click here to read the full story ... the Raabe College of Pharmacy in Ohio, Stanford Cancer ... Regional Healthcare in Kentucky gave a single dose of ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... EDITOR,S PICK: Predicting resistance to brain tumor chemotherapy ... lethal of all human brain tumors that originate in ... by both radiation therapy and chemotherapy with temozolomide. However, ... A team of researchers led by Sameer Agnihotri, at ...
... Medicine (BUSM) have identified for the first time the ... target against atherosclerosis resulting from a diet high in ... Circulation , may have significant public health implications. ... at low levels, and at higher levels during exercise ...
... have discovered how malaria manipulates the immune system to allow ... immune system pathway, the research team was able to cure ... published Dec. 11 in the Advance Online Publication of the ... a new approach for treating malaria that does not rely ...
... seedlings is important to crop growth and yield after ... stems, thick leaves, dark green leaves, and large white ... physiology are strongly influenced by the light spectrum, which ... has been shown to increase crop yield after planting ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 3Health News:Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... Jenner Stain is used for ... is one of the oldest stain ... provides results similar to that of ... to appear brighter red; basophilic granules ...
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Medicine Products: